Journal Article
. 2009 Dec;15(24).
doi: 10.1158/1078-0432.CCR-09-1450.

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

Joseph A Sparano 1 Lori J Goldstein  Barrett H Childs  Steven Shak  Diana Brassard  Sunil Badve  Frederick L Baehner  Roberto Bugarini  Steve Rowley  Edith Perez  Lawrence N Shulman  Silvana Martino  Nancy E Davidson  George W Sledge  Robert Gray  
  • PMID: 19996222
  •     28 References
  •     12 citations


PURPOSE: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-normal breast cancer patients treated with adjuvant doxorubicin-containing chemotherapy. EXPERIMENTAL DESIGN: RNA was extracted from archived tumor samples derived from 378 patients with stage I to III HR-positive, HER2-normal breast cancer and analyzed by reverse transcription-PCR for a panel of 374 genes, including the 21-gene recurrence score (RS). Patients were randomized to receive adjuvant doxorubicin plus cyclophosphamide or docetaxel in trial E2197, with no difference in recurrence seen in the treatment arms. All available recurrent cases were selected plus a nonrecurrent cohort. Cox proportional hazard models were used to identify relationships between gene expression and recurrence. RESULTS: TOP2A expression exhibited the strongest association with increased recurrence risk (P = 0.01), and was significantly associated with recurrence (P = 0.008) in a multivariate analysis adjusted for clinicopathologic features. Elevated TOP2A expression above the median was associated with a 2.6-fold increase (95% confidence interval, 1.3-5.2; P = 0.008) in risk of recurrence if the RS was <18, and a 2.0-fold increase (95% confidence interval, 1.2-3.2, P = 0.003) if there was an intermediate RS of 18 to 30. CONCLUSIONS: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker. (Clin Cancer Res 2009;15(24):7693-700).

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J M Harvey, G M Clark, C K Osborne, D C Allred.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334533
Highly Cited.
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
Scandinavian Breast Group Trial 9401, Minna Tanner, +7 authors, Jonas Bergh.
J Clin Oncol, 2006 May 10; 24(16). PMID: 16682728
Weighted analyses for cohort sampling designs.
Robert J Gray.
Lifetime Data Anal, 2008 Aug 21; 15(1). PMID: 18712477
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
Tian-Li Wang, Luis A Diaz, +12 authors, Victor E Velculescu.
Proc Natl Acad Sci U S A, 2004 Feb 19; 101(9). PMID: 14970324    Free PMC article.
Side effects of adjuvant treatment of breast cancer.
C L Shapiro, A Recht.
N Engl J Med, 2001 Jun 30; 344(26). PMID: 11430330
Highly Cited. Review.
An investigation of two multivariate permutation methods for controlling the false discovery proportion.
Edward L Korn, Ming-Chung Li, Lisa M McShane, Richard Simon.
Stat Med, 2007 Mar 16; 26(24). PMID: 17357994
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
Ying Chuan Hu, Richard A Komorowski, +4 authors, Steven A Ahrendt.
Clin Cancer Res, 2003 Oct 02; 9(11). PMID: 14519641
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Eric P Winer, Clifford Hudis, +19 authors, Mark R Somerfield.
J Clin Oncol, 2004 Nov 17; 23(3). PMID: 15545664
Highly Cited. Review.
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Lori J Goldstein, Anne O'Neill, +4 authors, Nancy E Davidson.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678836    Free PMC article.
HER-2 and topoisomerase II as predictors of response to chemotherapy.
Kathleen I Pritchard, Hans Messersmith, +3 authors, Bindi Dhesy-Thind.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258981
DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
F Zunino, G Capranico.
Anticancer Drug Des, 1990 Nov 01; 5(4). PMID: 1963303
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
A Rody, T Karn, +7 authors, M Kaufmann.
Breast Cancer Res Treat, 2008 Mar 15; 113(3). PMID: 18340528
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
Stephen E Jones, Michael A Savin, +17 authors, Lina Asmar.
J Clin Oncol, 2006 Dec 01; 24(34). PMID: 17135639
Highly Cited.
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Alessandra Gennari, Maria Pia Sormani, +4 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2007 Dec 27; 100(1). PMID: 18159072
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
Exposure stratified case-cohort designs.
O Borgan, B Langholz, +2 authors, J Pogoda.
Lifetime Data Anal, 2000 Apr 14; 6(1). PMID: 10763560
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Emilio Bria, Cecilia Nistico, +7 authors, Diana Giannarelli.
Cancer, 2006 May 02; 106(11). PMID: 16649217
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Marko Kornmann, Wolfgang Schwabe, +13 authors, Karl H Link.
Clin Cancer Res, 2003 Oct 02; 9(11). PMID: 14519634
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +21 authors, American Society of Clinical Oncology/College of American Pathologists.
Arch Pathol Lab Med, 2007 Jan 01; 131(1). PMID: 19548375
Highly Cited.
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820
Highly Cited.
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
Sunil S Badve, Frederick L Baehner, +13 authors, Joseph A Sparano.
J Clin Oncol, 2008 May 20; 26(15). PMID: 18487567
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.
Maureen Cronin, Mylan Pho, +5 authors, Joffre B Baker.
Am J Pathol, 2003 Dec 26; 164(1). PMID: 14695316    Free PMC article.
Highly Cited.
Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
Atocha Romero, Miguel Martín, +9 authors, Trinidad Caldés Llopis.
Am J Pathol, 2011 Mar 26; 178(4). PMID: 21435434    Free PMC article.
Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.
Joseph A Sparano, Lori J Goldstein, +13 authors, Robert Gray.
Clin Cancer Res, 2011 Sep 22; 17(22). PMID: 21933890    Free PMC article.
Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Atocha Romero, Trinidad Caldés, Eduardo Díaz-Rubio, Miguel Martín.
Clin Transl Oncol, 2012 Mar 01; 14(3). PMID: 22374418
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.
Lawrence J Solin, Robert Gray, +10 authors, Joseph A Sparano.
Breast Cancer Res Treat, 2012 May 02; 134(2). PMID: 22547108    Free PMC article.
TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.
Joseph A Sparano, Lori J Goldstein, +2 authors, Robert Gray.
Breast Cancer Res Treat, 2012 Jun 19; 134(2). PMID: 22706628    Free PMC article.
Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.
Anna J Zaczek, Aleksandra Markiewicz, +8 authors, Jacek Jassem.
Oncologist, 2012 Aug 09; 17(10). PMID: 22871798    Free PMC article.
Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets.
Joie N Marhefka, Rula A Abbud-Antaki.
PLoS One, 2012 Oct 11; 7(9). PMID: 23049944    Free PMC article.
Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research.
Vassiliki Kotoula, Konstantine T Kalogeras, +4 authors, George Fountzilas.
Virchows Arch, 2012 Dec 25; 462(2). PMID: 23262785    Free PMC article.
Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.
Hongmei Zheng, Xiang Li, +7 authors, Xinhong Wu.
Int J Nanomedicine, 2016 Nov 02; 11. PMID: 27799773    Free PMC article.
Ancestry as a potential modifier of gene expression in breast tumors from Colombian women.
Silvia J Serrano-Gómez, María Carolina Sanabria-Salas, +7 authors, Jovanny Zabaleta.
PLoS One, 2017 Aug 24; 12(8). PMID: 28832682    Free PMC article.
A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.
Joseph A Sparano, Robert Gray, +13 authors, Joan Jones.
NPJ Breast Cancer, 2017 Nov 16; 3. PMID: 29138761    Free PMC article.
Prognostic gene expression assays in breast cancer: are two better than one?
Joseph A Sparano.
NPJ Breast Cancer, 2018 May 31; 4. PMID: 29845110    Free PMC article.